Sonoma Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
54930008C5Z4F02SWO71 - ISIN
US83558L3033 (SNOA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. Read full profile
Fundamentals
- Net revenue
€12.72M - Gross margin
37.7% - EBIT
-€3.10M - EBIT margin
-24.4% - Net income
-€3.03M - Net margin
-23.8%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
| N/A | N/A |
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: November 9, 2018 (Q2 2019)